Sartar’s therapy method featured in Drug Target Review

Targeting phosphodiesterase 3A: discovery of a promising cancer therapy in Drug Target Review describes the science behind Sartar’s new cancer therapy, outlining emerging evidence that PDE3A protein-targeting compounds may induce sarcoma cell death by acting as a molecular glue between PDE3A and Schlafen 12 proteins.

Link to original article